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lumc.nl).INTRODUCTION
T cells derived from healthy stem cell donors can
mediate curative immune responses after allogeneic
stem cell transplantation (SCT) by eliminating (resid-
ual) hematopoietic tumor cell or life-threatening viral
infections. The first evidence for the crucial role of T
cells came from the observations that depletion of T
cells from a stem cell graft to prevent the development
of acute graft-versus-host disease (aGVHD)was associ-
ated with an increased incidence of relapse of the ma-
lignancy and life-threatening viral infections including
CMV disease and EBV-mediated posttransplant
lymphoproliferative disease (PTLD). Apparently, after
allogeneic SCT, T cells are not only responsible for
the detrimental GVHD, but also can mediate a graft-
versus-tumor (GVT) effect, and are essential for
long-term control of persistent endogenous viral
infections. Unmanipulated T cell populations derived
from the stem cell donor administered to the patient
may result in concurrent development of GVHD,
GVT, and antivirus responses. Immune suppression
to control GVHD may lead to reduction or elimina-
tion of GVT and pathogen-specific T cell responses.
Obviously, if T cell responses leading to GVHD could
be separated from GVL or pathogen-specific reactiv-
ity, morbidity and survival after allogeneic SCT can
be significantly improved. One approach to manipu-
late the effect of donor T cells after transplantation
has been the depletion of donor T cells from the graft
with postponed administration of donor T cells [1].
The rationale for this approach came from several
mouse and human studies illustrating that the recipient
microenvironment plays a significant role in the devel-
opment of GVHD [2]. Tissue damage during the con-
ditioning regimen leading to the initiation of
a ‘‘cytokine storm,’’ the strong lymphodepletion after
transplant leading to homeostatic proliferation of do-
nor T cells shortly after transplant, and the presence
of patient-derived activated dendritic cells (DC),
which are required for the induction of allo immune136responses, all contribute to this strong allo responses
immediately after transplantation. Postponed T cell
administration at the time of replacement of the
majority of recipient DC by donor DCs, after repair
of the tissue damage, and after partial reconstitution
of T cells in peripheral blood of patients, is associated
with lower risk of developing severe aGVHD. Admin-
istration of T cells from 6months after transplantation
can be performed with relatively low risk of inducing
severe GVHD, although chronic GVHD (cGVHD)
remains a significant complication. However, recur-
rence of the malignancy and the development of severe
opportunistic infections frequently take place within
the first half year after transplantation. Thus, although
postponed administration of T cells can result in less
severe GVHD, overall survival (OS) did not signifi-
cantly improve.
Delivering SCT that are free from GVHD while
conferring enhanced protection against malignant dis-
ease recurrence and viral reactivation is considered by
many transplanters to be a key goal (the ‘‘Holy Grail’’)
for improving transplant success. We will discuss sev-
eral approaches for the selective administration of non-
GVHD reactive donor T cells: selective allodepletion,
adoptive transfer of virus-specific T cells, allo-reactive
antitumor T cells recognizing minor histocompatibil-
ity antigens (mHag) or MHC molecules, or T cells
recognizing tumor-associated self-antigens.
SELECTIVE ALLODEPLETION
It is possible to separate GVHD from GVL effects
by coincubating donor lymphocytes with allogeneic
stimulator cells. Under these conditions, alloreactive
donor cells can be selectively identified by their surface
phenotype (eg, CD25, CD69), proliferative potential,
or preferential retention of photoactive dyes, and can
be subsequently targeted for elimination using an
immunotoxin, immunomagnetic bead separation,
fluorescence-activated cell sorting (FACS), or photo-
dynamic purging [3]. As demonstrated using standard
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actions (MLR) and the helperT-lymphocyte precursor
(HTLp) frequency assay, alloreactivity can be substan-
tially depleted in both the HLA-mismatched and
HLA-matched setting, while maintaining third-party
responses. Responder cells obtained after allodepletion
also maintain antitumor and antiviral activity. This
promising approach has been validated in a number
of centers in animal models, and 3 clinical trials using
aCD25 immunotoxin to selectively deplete alloreactiv-
ity (2 in haploidentical peripheral blood stem cell trans-
plantations (PBSCT) in pediatric patients and 1 in
adults with hematologicmalignancies inHLA identical
sibling transplants) indicate the concept is feasible, re-
ducing GVHD while promoting rapid immune recon-
stitution [4-7]. To overcome fluctuations in activation-
based surface marker expression and achieve a more
consistent and profound allodepletion, we developed
a photodepletion process targeting activation-based
changes in p-glycoprotein that result in an altered ef-
flux of the photosensitizer TH9402 [8]. Third-party
responses were maintained while the response to the
original stimulator was reduced 2-3 logs. Photodeple-
tion is currently being investigated in several clinical
trials in Europe and North America.
ADOPTIVE TRANSFER OF VIRUS-SPECIFIC T CELLS
An alternative approach to allodepletion that has
been evaluated for the prevention and treatment of
viral infection is to generate cytotoxic T cells ex vivo
for subsequent transfer to the recipient by repeated
stimulation with antigen-presenting cells (APCs) ex-
pressing viral antigens. One prerequisite for this strat-
egy is knowledge of which viral antigens are expressed
and are the most crucial for viral persistence and thus
suitable targets for immunotherapy strategies. The
viral antigens expressed at different stages of viral
infection have been well characterized for some viruses
such as cytomegalovirus (CMV) and EBV, but are less
well defined for other viruses that cause morbidity. It is
also necessary to have a source of the identified viral
antigen suitable for use in GMP manufacture and an
APC that will present peptides derived from this anti-
gen and express costimulatory molecules to produce T
cell activation. Initial studies evaluating virus-specific
CTLs have focused on CMV and EBV, as the immune
response is well understood and viral antigens are
defined [9].
CMV-SPECIFIC CTLS
CMVmatrix protein pp65 contains immunodomi-
nant epitopes against a range ofHLAbackgrounds, and
several studies have shown that CTLs specific for pp65
protect against CMVdisease in humans [10-14]. These
studies have used a variety of sources of CMV antigen
including CMV antigen and lysate, peptides, and anadenoviral vector-encoding pp65 antigen. APCs have
included dendritic cells, fibroblasts, and peripheral
blood mononuclear cells (PBMC). Prophylaxis with
adoptively transferred donor-derived, CMV-specific
CTL was first explored by Riddell and colleagues
[10]. When CD81T cell clones specific for the immu-
nodominant viral matrix proteins, pp65 and pp150,
were transferred to recipients ofmatched sibling grafts,
there were no adverse effects, CMV-specific immune
responses were reconstituted, and no patients devel-
oped CMV disease or late recurrences. Other studies
have confirmed the ability of adoptively transferred
CTLs to prevent and treat CMV reactivation
[11,13,14].
EBV-SPECIFIC T CELLS
In EBV PTLD in SCT recipients, the transformed
cells are of donor origin and express all latent cycle
virus-associated antigens, providing excellent targets
for virus-specific T cells. EBV-transformed B lympho-
blastoid cell lines (LCL) that express the same array of
viral proteins can be readily prepared from any donor,
and provide a source of APCs that endogenously
express the appropriate antigens for presentation of
HLA class I-restricted epitopes. Our group generated
EBV-specific T cell lines from donor lymphocytes and
used them as prophylaxis and treatment for EBV-
induced lymphoma in patients post-SCT [15]. The re-
sultant EBV-specific CTL are polyclonal and contain
both CD4- and CD8-positive EBV-specific T cells,
which is considered advantageous because the pres-
ence of antigen-specific CD4-helper T cells is impor-
tant for in vivo survival of cytotoxic CD8-positive T
cell populations. These CTLs have been administered
as prophylaxis or therapy for EBV lymphoma in high-
risk SCT recipients, and have survived for up to 86
months after infusion and were able to reduce the
high virus load that is observed in about 20% of
patients. EBV-CTL also appeared to prevent progres-
sion to EBV-lymphoma, because none of the 60 pa-
tients who received prophylactic CTL developed this
malignancy, compared with 11.5% of controls. Fur-
ther, 5 of 6 patients who received CTL as treatment
for overt lymphoma achieved complete remissions.
In the patient who failed to respond, the tumor was
transformed with a virus that had deleted the 2 CTL
epitopes for which the donor CTL line was specific.
Other studies have confirmed the activity of EBV-
specific CTLs posttransplant [16].
MULTIVIRUS-SPECIFIC CTLS
Although effective, these strategies only target 1 of
the many viruses that cause morbidity posttransplant.
We have therefore developed an approach to generate
CTL that can restore cellular immunity to CMV,
EBV, and adenovirus simultaneously [14] by using
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enoviral vector encoding the CMV antigen pp65 for
the initial stimulation followed by stimulations with
EBV-lymphoblastoid cell lines transduced with the
same vector. Fourteen of 15 CTL lines generated
showed specific activity against all 3 viruses, and 1
line recognized CMV and EBV but not adenovirus tar-
gets. We have treated 14 patients in a phase I prophy-
laxis study, and observed up to an 8-fold increase in
CMV- and EBV-specific T cells, and these patients
were able to control viral reactivations. We observed
an increase in adenovirus-specific T cells in 5 patients
who had evidence of adenovirus infection preinfusion,
and all were able to clear their infections. Of note, 1 of
these patients who received CTLs when he had pro-
gressive adenoviral pneumonia had a rise in adenovi-
rus-specific T cells postinfusion coincident with
a complete recovery. Multivirus CTLs can therefore
expand in response to viral challenge and produce clin-
ically relevant effects against all 3 viruses.We have also
evaluated the use of bispecific lines targeting adenovi-
rus and EBV in 12 recipients of CMV seronegative
products [17]. Again, increased EBV-specific T cell
frequency was detected in all patients, but rises in
adenovirus-specific T cell frequency was only seen in
patients with active infection. Expansion of virus-
specific CTLs may therefore require the presence of
antigen to stimulate the infused cells. We are currently
modifying the construct to express additional viral
antigens to provide broader coverage.
EXTENDING THE APPLICABILITY OF VIRUS-SPECIFIC
CTLS
Although these studies effectively demonstrate
proof of principle, the wider application of this ap-
proach is limited by the time required for CTL gener-
ation using current good manufacturing processing
techniques. Rapid selection techniques such are tetra-
mer selection and gamma-interferon capture are there-
fore being evaluated. CMV-pp65-specific T cells from
stem cell donors were selected from peripheral blood
using tetramers, and after direct infusion into patients
expanded by several logs and reconstituted immunity
to CMV [12]. A concern with this approach is that
the product has limited specificity for 1 epitope, and
is only available for some HLA types. Gamma-inter-
feron capture has been used to isolate adenovirus-
specific donor T cells that were infused into 9
children with systemic adenovirus infection with
responses in 5of 6 evaluable patients [18]. An alternative
approach is to use closely matched banked allogeneic
lines that could be available as an ‘‘off-the-shelf’’ prod-
uct. A concern with this approach is that persistence of
a mismatched product may be suboptimal. However,
a recent Phase II study using EBV-specific CTLs to
treat PTLD after solid organ transplant or SCT hasshownanencouraging response rate of 64%,withbetter
responses with more closely matching lines [19].
TREATMENT OF HEMATOLOGIC MALIGNANCIES WITH
ALLOREACTIVE T CELLS
The observation that autologous SCT and alloge-
neic SCT using homozygous twins as donors did not
result in a similar control of the hematologic malig-
nancy after transplantation compared to allogeneic
SCT has indicated that the mere presence of T cells
in the graft is not sufficient to elicit a GVT reactivity
[20]. Apparently, genetic differences between donor
and patients strongly contribute to not only GVHD
but also a GVT response. After partially HLA-
matched allogeneic SCT, the immune response may
likely to be directed against the mismatched HLA
allele, because the number of alloreactive T cells in
peripheral blood of normal individuals is relatively
high, with frequencies of up to 1% of circulating T
cells. After HLA-matched allogeneic transplantation,
mHag are the most likely targets for the immune-
reactivity after allogeneic SCT. Although alloreactive
T cell responses against HLA or mHag can elicit
both GVHD and GVT, characterization of the fine
specificities of the T cells has indicated that GVHD
responses can be separated from alloreactive GVT.
mHAG
mHag are defined as target antigens that are capa-
ble of eliciting an allogeneic immune response medi-
ated by T cells from a fully HLA-identical donor.
The human genome contains many single nucleotide
polymorphisms (SNP). If an SNP is present within
the coding region of a gene, this may lead to amino
acid substitutions in the protein. If a peptide derived
from a polymorphic gene is presented by HLA mole-
cules, differences in the peptide content between
donor and recipient may lead to an allo immune
response. The polymorphism in the gene can lead to
differences in amino acid sequence of the peptides
presented in the groove of the HLA molecules, to
differential binding of peptides to the MHCmolecule,
or to differential processing of the peptide leading to
the presence of absence of the potentially immuno-
genic peptide in HLA molecules. Donor T cells that
are capable of recognizing immunogenic peptides on
cells from the patient may lead to destruction of the
cells expressing these polymorphic genes. Obviously,
a prerequisite for the destruction of the target tissues
by the immune response is the presence of the present-
ing HLA molecules on the target cells as well as the
expression and processing of the protein encoding
the mHag in these tissues. Thus, both the tissue distri-
bution of the protein encoding the mHag as well as the
expression of the MHC molecules will determine the
likelihood of destruction of the patient-derived tissues.
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After transplantation, normal hematopoiesis in the
patient is replaced by donor hematopoiesis. Residual
tumor cells are of recipient origin, and some residual
normal hematopoietic cells may also be derived from
the patient. An allogeneic T cell response recognizing
polymorphic antigens expressed on hematopoietic
cells from the recipient that are coexpressed on the
hematopoietic tumor cells will lead to eradication of
the tumor and elimination of residual recipient hema-
topoietic cells without impairment of donor hemato-
poiesis in the patient. Whether or not this GVT
response will be accompanied by GVHD may depend
on the tissue distribution of the MHC molecules and
the polymorphic protein encoding the mHag in non-
hematopoietic tissues. Several mHag have been found
to be restricted to hematopoietic tissues. For instance,
the genes encoding the mHag HA-1, HA-2, HB-1,
BCL2A1, LRH-1, PANE1, and LB-ECGF-1H have
been found to be relatively restricted to cells of hema-
topoietic origin. Analyses of immune responses from
patients successfully treated with donor lymphocyte
infusion (DLI) have illustrated that the development
of a T cell response against the hematopoiesis-associ-
ated mHag can result in a potent antitumor effect,
conversion to full donor chimerism, with no or only
temporary GVHD [21]. Because many hematopoietic
cells including dendritic cells (DC) are present in nor-
mal tissues, an immune response against polymorphic
antigens expressed on hematopoietic cells may lead to
an inflammatory response in these tissues, but the
severity of this immune response is likely to be low.
Analyses of patients successfully treated with DLI
have demonstrated that the kinetics of the immune re-
sponse against mHag-specific antigens associated with
an antitumor effect resembles the development of an
immune response against viral infections. After the
initial rise of antigen-specific T cells to high frequen-
cies exceeding 1% of all circulating T cells, the
immune response declines after eradication of the
tumor and a memory response may develop. This
memory response may be relevant for sustained and
prolonged suppression of the tumor. Similarly, we
have found strong T cell responses against class II-as-
sociated antigens in patients successfully responding
to DLI in the absence of GVHD. The limited distri-
bution of MHC class II, mainly restricted to hemato-
poietic cells, may allow the development of immune
responses against class II antigens as relatively
tumor-specific.
IN VITRO GENERATION OF mHAG-SPECIFIC T CELLS FOR
TREATMENT OF LEUKEMIA
Because we demonstrated a potential clinical effect
of treatment of patients with refractory hematologic
malignancies with in vitro generated leukemia-reactiveT cells [22], several approaches are being explored to
isolate mHag-specific T cells for adoptive transfer,
including the isolation of antigen-specific T cells using
multimeric peptide/major histocompatibility com-
plexes (MHC) coupled to immunomagnetic beads, or
based on specific production of INF-g by activated
T cells after antigen-specific triggering [23]. Alterna-
tively, large numbers of antigen-specific T cells can
be generated using T cell receptor (TCR) gene trans-
fer. High-affinity mHag-specific TCRs have been
characterized and isolated from high avidity T cells.
Following transfer of the TCR a and b genes to pri-
mary donor T cells, the specificity of the TCR can
be transferred to these T cells. Because pathogen-spe-
cific T cells like CMV-specific T cells are responsible
for an effective immune response after transplantation
with control of CMV, the possibility to transfer
mHag-specific TCRs to these virus-specific T cells
has been explored [24]. Transfer of the TCRs resulted
in combined reactivity of these reengineered T cells
against mHag and the pathogens. Because the persis-
tent presence of CMV antigen or other relevant path-
ogens after transplantation in the recipient may lead to
persistent activation of these specific transduced T
cells, a memory T cell response may be obtained,
allowing persistent immune surveillance against both
pathogens and residual tumor cells.
LEUKEMIA-SPECIFIC ANTIGENS AS TARGETS FOR GVL
In addition to mHag, tumor cells can overexpress
proteins that are often intrinsic to the maintenance of
the malignant phenotype. Peptide sequences from
these proteins can be antigenic by virtue of their
overexpression (eg, proteinase 3 [PR3] and human
neutrophil elastase [HNE]), aberrant expression (eg,
onco fetal antigens such as Wilms tumor 1), or
uniqueness (eg, fusion proteins such as the BCR-
ABL breakpoint sequence of the Ph chromosome).
Because they are not usually alleleic, peptides derived
from these proteins behave as self-antigens rather
than mHag [25]. Nevertheless, it is clear that low fre-
quencies of CTL recognizing PR3, HNE, and WT1
(but not BCR-ABL) circulate in normal individuals
and are increased in patients with leukemia and
more so after allogeneic SCT [26,27]. These studies
suggest that stimulation by leukemia, especially after
SCT, can induce expansion of antigen-specific effec-
tor-memory CTL from a pool of antigen-experienced
central memory cells. The occurrence of low fre-
quencies of leukemia-specific CTL in normal donors
has encouraged clinical trials with peptide vaccines
against HLA A0201 and HLA A 2401-restricted pep-
tides of PR3 and WT1 [28]. Notable responses
including complete remissions have been reported
using PR1 peptide vaccine to treat patients with
relapsed myeloid malignancies after allogeneic SCT
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cific T cell clones from the donor can transfer and
expand in the recipient supports the development of
new strategies for the adoptive transfer of GVL
immunity. First, vaccination of a donor not yet toler-
ized to the leukemia could increase the frequency of
leukemia-specific T cells conveyed in the graft. Sec-
ond, the cytokine storm and the lymphopenia that
follows the conditioning regimen may be favorable
to the expansion of these leukemia-specific CTL,
which could be further boosted by early vaccination
of the transplant recipient.
FUTURE PROSPECTS—COMBINING STRATEGIES FOR THE
‘‘PERFECT TRANSPLANT’’
Although the approaches we have described to
shape immune reconstitution after SCT are currently
being developed separately at different centers, the
successful introduction of these individual strategies
could be only a prelude to the design of future trans-
plants where the techniques are combined to opti-
mize GVT effects and antimicrobial immunity. For
example, vaccination of the donor with leukemia-
antigen-specific peptides could be used to induce
antigen-specific T cells in donor lymphocytes for fur-
ther expansion in vitro for adoptive transfer to the re-
cipient. Selective TCD transplants (which would not
require posttransplant immunosuppressive GVHD
prophylaxis) would be an ideal platform for the
adoptive transfer of antigen-specific T cells in the
first few weeks after SCT when the lymphopenic
milieu best favors antigen-specific T cell expansion.
Finally, adoptively transferred T cells could be
further boosted by the relevant vaccine. Although
we are aware that the careful construction of post-
transplant immunity is likely to remain technically
challenging and expensive, the effort taken to create
the ‘‘perfect transplant’’ will be justified economically
if it is demonstrated that most patients have a compli-
cation-free posttransplant course, without disease
recurrence.
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